Published in Blood Coagul Fibrinolysis on June 01, 1991
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (2006) 2.01
Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet (2000) 1.69
Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed) (2012) 1.28
Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2011) 0.80
The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV. PLoS One (2017) 0.75
The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg (2006) 2.74
[Treatment of primary hypercholesterolemia with pravastatin. A placebo-controlled trial]. Ugeskr Laeger (1993) 2.05
[Venous thromboembolism--incidence and risk factors in Oslo]. Tidsskr Nor Laegeforen (1998) 2.03
Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med (2006) 2.02
Validity of an exam assessment in surgical skill: EBSQ-VASC pilot study. Eur J Vasc Endovasc Surg (2004) 1.48
Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest (2002) 1.46
Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem (1990) 1.46
Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH). Thromb Res (1977) 1.46
Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res (1988) 1.43
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin. Eur Heart J (1993) 1.42
Heparin cofactor activity measured with an amidolytic method. Thromb Res (1975) 1.42
The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res (1976) 1.41
[Alcohol abuse as the cause of admission to a medical department]. Tidsskr Nor Laegeforen (1990) 1.39
Acyclovir crystalluria. Scand J Infect Dis (1988) 1.39
Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol (1966) 1.26
Immunological studies on human antithrombin 3. Influence of age, sex and use of oral contraceptives on serum concentration. Scand J Haematol (1970) 1.22
Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma. Scand J Clin Lab Invest (1970) 1.21
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med (2001) 1.21
Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res (1976) 1.18
Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem (1996) 1.18
Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol (1989) 1.16
Bed rest and increased diuretic treatment in chronic congestive heart failure. Eur Heart J (1985) 1.14
Binding of thrombin to antithrombin III. Scand J Clin Lab Invest (1969) 1.12
The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl (1979) 1.07
Anticoagulant activity of heparin: assay of bovine, human and porcine preparations by amidolytic and clotting methods. Thromb Res (1977) 1.06
Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest (1968) 1.06
Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res (1978) 1.03
Assay of progressive antithrombin in plasma. Thromb Diath Haemorrh (1970) 1.02
Comparison of overnight, morning and 24-hour urine collections in the assessment of diabetic microalbuminuria. Diabet Med (1988) 1.02
Association of IDDM and attenuated response of 2',5'-oligoadenylate synthetase to yellow fever vaccine. Diabetes (1989) 0.99
The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res (1989) 0.98
The effect of antithrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemost (1976) 0.98
A prospective study of 1212 cases of acute poisoning: general epidemiology. Hum Toxicol (1984) 0.98
Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther (1988) 0.98
Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest (1982) 0.97
Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest (1992) 0.95
Molar antithrombin concentration in normal human plasma. Haemostasis (1983) 0.95
Antifactor Xa activity measured with amidolytic methods. Haemostasis (1976) 0.93
Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol (1998) 0.92
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol (1990) 0.92
Inhibition of the thrombin-fibrinogen reaction by heparin and purified cofactor. Scand J Haematol (1968) 0.92
Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis (1978) 0.92
Oral contraceptives and low antithrombin-3 concentration. Lancet (1970) 0.92
Changes in antithrombin 3 levels following cessation of anticoagulant therapy. Acta Med Scand (1973) 0.91
Socio-economic status influences blood pressure control despite equal access to care. Fam Pract (2012) 0.91
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis (1989) 0.91
Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol (1992) 0.90
Recurrent endocarditis in silver-coated heart valve prosthesis. J Heart Valve Dis (1999) 0.90
Antifactor Xa activity in thrombophilia. Studies in a family with Ar-III deficiency. Scand J Haematol (1977) 0.90
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Acta Paediatr (1995) 0.90
Antithrombin 3. Protection against death after injection of thromboplastin. Science (1969) 0.89
Antithrombin-3 concentration and ABO blood-groups. Lancet (1971) 0.89
Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol (1992) 0.89
Platelet aggregation induced by ADP from unsheared erythrocytes at physiological Ca++-concentration. Br J Haematol (1981) 0.89
Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand (1988) 0.89
Biological action and clinical significance of antithrombin III. Haematologia (Budap) (1984) 0.88
The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis (1992) 0.88
Undiagnosed dysglycaemia and inflammation in cardiovascular disease. Eur J Clin Invest (2006) 0.88
Separation and characterization of two fibrinolytic inhibitors from human placenta. Thromb Diath Haemorrh (1971) 0.88
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol (1997) 0.87
Studies on soluble fibrin in plasma. I. N-terminal analysis of a modified fraction I (Cohn) from normal and thrombin-incubated plasma. Scand J Clin Lab Invest (1971) 0.87
Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis (1991) 0.87
A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res (1987) 0.86
Inhibition of the thrombin-fibrinogen reaction by heparin in the absence of cofactor. Scand J Haematol (1968) 0.86
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol (1993) 0.86
Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Eur J Pediatr (1996) 0.86
Detection of a single base deletion in codon 424 of the low density lipoprotein receptor gene in a Danish family with familial hypercholesterolemia. Atherosclerosis (1994) 0.85
Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med (1995) 0.85
Danish singles have a twofold risk of acute coronary syndrome: data from a cohort of 138 290 persons. J Epidemiol Community Health (2006) 0.85
Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem (1989) 0.85
Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis (1986) 0.85
Clinical course in acute self-poisonings: a prospective study of 1125 consecutively hospitalised adults. Hum Toxicol (1984) 0.85
Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med (2004) 0.84
Protein C: a simplified semi-automated activity assay. Thromb Res (1986) 0.84
Major operations, hemostatic parameters and venous thrombosis. Thromb Res (1974) 0.84
A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost (1990) 0.83
Atrial fibrillation and left atrial enlargement: cause or effect? J Intern Med (1991) 0.83
ELISA analysis of IgA subclass antibodies to dietary antigens. Elevated IgA1 antibodies in children with coeliac disease. Int Arch Allergy Appl Immunol (1988) 0.83
Increased plasma thrombomodulin in cancer patients. Thromb Haemost (1993) 0.83
N-terminal analysis during coagulation of purified human fibrinogen, fraction I, and plasma. Scand J Clin Lab Invest (1965) 0.82
Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res (1996) 0.82
On-pump versus off-pump coronary artery bypass: independent risk factors and off-pump graft patency. Eur J Cardiothorac Surg (2001) 0.82
Sequelae to genital trauma in torture victims. Arch Androl (1983) 0.82
Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand (1987) 0.82
Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis (1991) 0.82
High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand (1989) 0.82
Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res (1984) 0.82
Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost (1988) 0.82
Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Ren Physiol (1986) 0.82
Low antithrombin III in acute hepatic failure at term. Scand J Haematol (1982) 0.82
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost (1998) 0.81
The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond) (1994) 0.81